• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Summit Raises $200 Million; Also Expands License Territories for Ivonescimab

cafead

Administrator
Staff member
  • cafead   Jun 03, 2024 at 12:12: PM
via
  • $200 Million in Net Proceeds Raised at Premium to Previous Closing Price
  • In Separate Transaction, Summit Expanded License Territories for Ivonescimab in Deal with Akeso to include Latin America, Middle East, and Africa
  • Expansion Is in Addition to Existing License Territories of US, Canada, Europe, and Japan

article source
 

<